Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo sinh học: " Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis | BioMed Central Virology Journal Methodology Open Access Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis Edyta Zielinska Daiqing Liu Hong-Yin Wu Jorge Quiroz Ruth Rappaport and Da-Ping Yang Address Clinical Immunology and Virology Wyeth Vaccines Research Pearl River NY. USA Email Edyta Zielinska - esz96@hampshire.edu Daiqing Liu - Liu3@Wyeth.com Hong-Yin Wu - Wuh@Wyeth.com Jorge Quiroz - QuirozJ@Wyeth.com Ruth Rappaport- Rappapr@Wyeth.com Da-Ping Yang -YangD@Wyeth.com Corresponding author Published 09 November 2005 Received 08 June 2005 Accepted 09 November 2005 Virology Journal 2005 2 84 doi 10.1186 1743-422X-2-84 This article is available from http www.virologyj.com content 2 1 84 2005 Zielinska et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Respiratory syncytial virus RSV is the major cause of lower respiratory tract infection in infants and young children. Although several experimental RSV vaccines are under investigation immuno therapy is the only treatment currently available. In assessing the immunogenicity of various vaccine formulations a plaque reduction neutralization assay for the evaluation of RSV neutralizing antibody has been widely used. The method produces reliable results but it is tedious and labor intensive as it relies on manual counting by laboratory personnel. To facilitate evaluation of phase II and phase III vaccine clinical trials a more rapid reliable and efficient neutralization assay is needed. Results An improved microneutralization assay for quantifying RSV neutralizing antibodies was developed using an ImmunoSpot Series I Analyzer Cellular Technology Ltd. Cleveland OH for .